Synapse - Works

Results (4808)

The RegiSONIC Disease Registry Study: Safety and effectiveness of vismodegib or surgery as primary treatment in patients with locally advanced basal cell carcinoma

Meeting Abstract

Lacouture, M.; Guillen, J.; Kudchadkar, R.; Rogers, G.; Olencki, T.; Tang, J. Y.; Yoo, S.; Dawson, K.; Mun, Y.; Sekulic, A.
European Journal of Cancer (2015)

Fulltext@MSK | Save

Real-world treatment of vismodegib (VISMO)-related adverse events (AEs) in patients with locally advanced basal cell carcinoma: Report from the RegiSONIC Disease Registry Study

Meeting Abstract

Lacouture, M.; Guillen, J.; Kudchadkar, R.; Rogers, G.; Olencki, T.; Tang, J.; Yoo, S.; Dawson, K.; Mun, Y.; Sekulic, A.
European Journal of Cancer (2015)

Fulltext@MSK | Save

Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067)

Meeting Abstract

Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Wagstaff, J.; Hogg, D.; Hill, A.; Carlino, M. S.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma

Meeting Abstract

van Herpen, C.; Postow, M. A.; Carlino, M. S.; Kalkavan, H.; Weise, A.; Amaria, R. N.; De Vos, F.; Carvajal, R. D.; Matano, A.; Bhansali, S.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial

Meeting Abstract

Soria, J. C.; Goldman, J. W.; Wakelee, H.; Gadgeel, S.; Camidge, D. R.; Solomon, B.; Yu, H.; Oxnard, G. R.; Ou, S. H.; Papadimitrakopoulou, V.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

Rociletinib treatment and outcomes in non-small cell lung cancer (NSCLC) patients with negative central testing for T790M

Meeting Abstract

Solomon, B.; Wakelee, H.; Sequist, L. V.; Gadgeel, S.; Soria, J. C.; Goldman, J. W.; Yu, H.; Camidge, D. R.; Papadimitrakopoulou, V.; Matheny, S.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC)

Meeting Abstract

Calvo, E.; Lopez-Martin, J. A.; Bendell, J.; Eder, J. P.; Taylor, M.; Ott, P. A.; Pietanza, M. C.; Horn, L.; Jäger, D.; De Braud, F.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)

Meeting Abstract

Hellmann, M. D.; Rizvi, N.; Gettinger, S. N.; Goldman, J.; Chow, L. Q.; Juergens, R.; Borghaei, H.; Brahmer, J.; Shen, Y.; Harbison, C. T.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses

Meeting Abstract

Gettinger, S. N.; Hellmann, M. D.; Shepherd, F. A.; Antonia, S. J.; Brahmer, J.; Chow, L. Q.; Goldman, J.; Juergens, R.; Borghaei, H.; Ready, N. E.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC)

Meeting Abstract

Gettinger, S. N.; Horn, L.; Ramalingam, S. S.; Spigel, D. R.; Paz-Ares, L.; Paik, P.; Reck, M.; Reckamp, K.; Mazieres, J.; Stinchcombe, T.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save